ReviewDigestive diseases and sciences2011
The regulation of thymic stromal lymphopoietin in gut immune homeostasis.
Review in Digestive diseases and sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- Article
- TSLP Protects Corneas From Pseudomonas aeruginosa Infection by Regulating Dendritic Cells and IL-23-IL-17 Pathway.Investigative ophthalmology & visual science · 2018Article
- Functional Starters for Functional Yogurt.Foods (Basel, Switzerland) · 2015Article
- Network analysis reveals functional cross-links between disease and inflammation genes.Scientific reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymic stromal lymphopoietin is a novel IL-7-like cytokine that exerts immunomodulatory effects and is constitutively expressed by intestinal epithelial cells in response to commensal bacteria colonization. Thymic stromal lymphopoietin can directly or indirectly promote Th2 and Treg responses, and is believed to inhibit Th1 and Th17 responses and limit the expression of proinflammatory cytokines such as IL-17 and IFN-γ. In response to infection by enteric pathogens, intestinal epithelial cells upregulate thymic stromal lymphopoietin expression in order to generate balance between inflammation and immune clearance. Recently, however, aberrant expression of thymic stromal lymphopoietin has been associated with inflammatory bowel disease. Thus, we sought to examine the relationship between the TLSP-TSLPR pathway and inflammation in hopes of contributing to the search for a novel therapeutic target to treat a variety of inflammatory diseases, including inflammatory bowel disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.